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Asoluble tissue factor–annexin V chimeric protein has both procoagulant
and anticoagulant properties
Xin Huang, Wei-Qun Ding, Joshua L. Vaught, Roman F. Wolf, James H. Morrissey, Roger G. Harrison, and Stuart E. Lind
Tissue factor (TF) initiates blood coagula-
tion, but its expression in the vascular
space requires a ﬁnite period of time. We
hypothesized that targeting exogenous
tissue factor to sites of vascular injury
could lead to accelerated hemostasis.
Sincephosphatidylserine(PS)isexposed
on activated cells at sites of vascular
injury, we cloned the cDNA for a chimeric
protein consisting of the extracellular do-
main of TF (called soluble TF or sTF) and
annexin V, a human PS-binding protein.
Both the sTF and annexin V domains had
ligand-binding activities consistent with
their native counterparts, and the chi-
mera accelerated factor X activation by
factor VIIa. The chimera exhibited bipha-
sic effects upon blood coagulation. At
low concentrations it accelerated blood
coagulation, while at higher concentra-
tions it acted as an anticoagulant. The
chimera accelerated coagulation in the
presence of either unfractionated or low-
molecular-weight heparins more potently
than factor VIIa and shortened the bleed-
ing time of mice treated with enoxaparin.
The sTF–annexin V chimera is a targeted
procoagulant protein that may be useful
inacceleratingthrombingenerationwhere
PS is exposed to the vasculature, such as
may occur at sites of vascular injury or
within the vasculature of tumors. (Blood.
2006;107:980-986)
© 2006 by TheAmerican Society of Hematology
Introduction
The generation of thrombin is crucial for normal hemostasis.
Thrombin generation is initiated by the interaction of the plasma
serine protease, factor VIIa, with its protein cofactor, tissue factor
(TF).TF is a membrane-bound protein not expressed on the surface
of cells in contact with the bloodstream until they become
activated.1 Upon its expression,TF binds either factorVII (promot-
ing its activation to factor VIIa) or factor VIIa, increasing its
catalytic efﬁciency in converting factor X to factor Xa. Expression
of TF’s extracellular domain (amino acids 1-219) of TF in E coli
generates an approximately 26-kDa polypeptide that retains the
ability to bind to factor VIIa and to allosterically activate it. The
truncated TF (called soluble TF or sTF) does not bind to cellular
membranes and is therefore much less efﬁcient than native TF in
promoting factor VII autoactivation or activation of factor X by
factorVIIa.2,3 Engineering of the cDNAencoding sTF so that it was
expressedonthesurfaceofmammaliancellsasaglycosylphosphati-
dylinositol-anchored protein resulted in a protein with the same
speciﬁc procoagulant activity as native TF, underscoring the
importance of membrane attachment for this protein.4
It has long been recognized that congenital factor VIII deﬁ-
ciency is characterized by abnormal thrombin generation when
blood coagulation is triggered by low concentrations of TF.5 More
recently recognized is the fact that disorders of platelet function are
also associated with decreased thrombin generation.6-9 The vitamin
K–dependent blood coagulation proteins, which are required for
thrombin generation, assemble on the surface of activated platelets,
endothelial cells, and/or monocytes by binding to anionic phospho-
lipids, especially phosphatidylserine (PS). Thrombin, a potent platelet
agonist, ampliﬁes the activation of platelets initiated by contact with
subendothelial collagen exposure. Delayed thrombin generation may
therefore underlie or amplify the bleeding tendency accompanying
disorders of plasma coagulation factors or blood platelets.
Others have reported that the intravenous injection of thrombo-
plastin (membrane-bound TF) into animals results in generalized
activation of the coagulation system,10,11 as does injection of both
sTF and factor VIIa. The latter results in beneﬁcial effects upon
bleeding in experimental animals, suggesting that sTF might serve
as the basis of a therapy designed to reduce bleeding.12
We hypothesized that targeting sTF to sites of vascular injury
could maximize its ability to function as a hemostatic agent while
minimizing the chance of inducing disseminated intravascular
coagulation (DIC). Although targeting might be undertaken by
using an antibody speciﬁc for activated platelets, endothelial cells,
or monocytes, a targeting moiety capable of binding to all 3 cell
types would be preferable, insofar as it would be less sensitive to
alterations in the number of targeted cells that might be present in
any given individual. Since each of the cell types of interest
expresses PS on its surface when activated, we considered targeting
sTF to PS-containing membranes by coupling it to annexin V, a
human PS-binding protein that has been shown to bind to activated
platelets, endothelial cells, and monocytes.13-15Arguing against the
use of annexinVwas the fact that it is an anticoagulant protein, due
to its ability to compete with vitamin K–dependent proteins for
binding to PS-containing membranes.16
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amino acid residues 1 to 218 of TF (sTF), a linker region, and the
entire coding sequence for annexin V has both pro- and anticoagu-
lant properties. By using a chimera (called sTFAA-annV) whose
sTF domain was functionally impaired by alanine substitution, we
have found that the predominance of one or the other of these
opposing domains varies with the local concentration of PS, in a
predictable manner.
Materials and methods
Materials
Recombinant membrane-anchored TF, recombinant sTF (TF1-219), and
monoclonal antibodies to factorVII andTF were prepared as described.17-19
A monoclonal antibody reacting with the His6 tag of recombinant proteins
was from Cell Signaling Technology (Beverly, MA). Chromozym t-PA
(N-methysulfonyl-D-phenylalanylglycyl-L-arginine-4-nitroanilide acetate)
and Chromozym X (N-methoxycarbonyl-D-norleucyl-glycyl-L-arginine-4-
nitranilide acetate) were from Roche Diagnostics (Indianapolis, IN).
Puriﬁed human factors X, Xa, VII, and VIIa were from Enzyme Research
Laboratories (South Bend, IN). Unless otherwise speciﬁed, all other
reagents were from Sigma Chemical (St Louis, MO).
Phospholipids were obtained from Avanti Polar Lipid (Alabaster,
AL) as stock solutions in chloroform and used to prepare unilamellar
phospholipid vesicles.20 Aliquots were mixed at a molar ratio of
phosphatidylcholine (PC) to PS of 4:1, and the chloroform was removed by
evaporation under argon. Phospholipids were resuspended in 0.1 M NaCl,
0.05 M Tris-HCl, pH 7.5, and sonicated until the suspension was almost
clear, yielding PC/PS vesicles. The phospholipid concentration was deter-
mined by phosphate analysis.21
Relipidation of TF into phospholipid vesicles was performed using the
octyl-beta-D-glucopyranoside method,22,23 typically at a TF-phospholipid
molar ratio of 1:8700. The effective TF concentration was determined by
titrating with increasing concentrations of factor VIIa in solutions contain-
ing Chromozym t-PA and comparing the resulting amidolytic activity to
that obtained by incubating factor VIIa with known concentrations of sTF.
The phospholipid concentration of the TF preparation was determined by
phosphate analysis21 so that comparable amounts of PS were present when
TF was compared directly to sTF-annV.
Fluorescein isothiocyanate (FITC)–annexin V was prepared by incubat-
ing FITC with annexin V at a 2:1 molar ratio for 1 hour in the dark at room
temperature in 0.5 M carbonate buffer, pH 9.5. Unbound FITC was
removed by gel ﬁltration in 150 mM NaCl, 0.01 M Tris-HCl, pH 8.2,
followed by dialysis against the same buffer for an additional 48 hours.
Construction of expression vectors
Annexin V cDNA (in the pET-22b() vector) was a generous gift from Dr
Antony Rosen. The sTF-annV construct was generated by ligating the
cDNA encoding amino acids 1 to 218 of TF to the 5 end of the annexin V
cDNA. The sTF cDNA was cloned by polymerase chain reaction (PCR)
usingtheforwardprimer5-CATGCCATGGCAGGCGCTTCAGGCACTA-
CAAATAC-3 and the reverse primer 5-CCCAAGTCTTGGGTTCTCT-
GAATTCCCCTTTCTC-3. A linker sequence encoding (GGGGS)3 was
inserted between the sTF and annexin V cDNA using QuikChange Multi
Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) with the follow-
ing primer: 5-GGGGAATTCAGAGAAGGTGGCGGTTCAGGCGGTG-
GAGGTTCAGGAGGTGGCGGATCAATGGCACAGGTTCTC-3. The
sTF-annV gene was cloned into the NcoI and HindIII sites of the
pET-22b() vector. This vector codes for a protein with a His6-tag at the
carboxy terminus.
A chimera composed of a mutated form of sTF24 linked to annexin V
(sTFAA-annV) was created by site-directed mutagenesis. Residues 165 and
166 of sTF were mutated with the QuikChange Multi Site-Directed
Mutagenesis Kit (Stratagene) from lysine to alanine using the primer
5-CTTTATTATTGGAAATCTTCAAGTTCAGGAGCCGCAACAGCC-
AAAACAAACACTAATGAGTTTTTG-3. The sTFAA-annV gene was
cloned into the NcoI and HindIII sites of pET-22b(). DNA sequencing
conﬁrmed the composition of all 3 constructs.
Expression and puriﬁcation of sTF-annV, sTFAA-annV,
and annexin V
The pET-22b() vectors with the sTF-annV, sTFAA-annV, or annV genes
were inserted into E coli strain BL-21/DE3 (Novagen, Madison, WI). This
vector provides a signal peptide that directs the recombinant protein to the
periplasmic space. Expression was induced when the A600 of the bacterial
suspension reached 0.8 by adding 0.3 mM isopropyl-beta-D-thiogalactopy-
ranoside (IPTG) for 15 hours at 25°C. Cells were harvested and subjected to
osmotic shock (5 mM MgSO4), and the periplasmic fraction was collected.
Recombinant proteins were puriﬁed by immobilized metal afﬁnity chroma-
tography using a His-Select column (Sigma, St Louis, MO) equilibrated
with 0.3 M NaCl, 0.05 M NaH2PO4, pH 8.0. The column was washed with
the same solution in the presence of 10 and 20 mM imidazole and then
eluted with 250 mM imidazole. The eluate was dialyzed against 0.1 M
NaCl, 50 mM Tris-HCl, pH 7.4. The purity and identity of recombinant
proteins were examined by sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS-PAGE) and Western blotting.
Phospholipid binding assay
The afﬁnity of chimeras for phospholipid vesicles containing PS was
determined by modiﬁcations of published assays25,26 using a commercially
available aPTT coagulation reagent (Dade Actin FSL; Dade Behring,
Newark, DE) as the source of PS. The reagent was reconstituted according
to the manufacturer’s instructions and diluted 1:10 with 140 mM NaCl, 0.01
M HEPES, pH 7.5 (HBS) plus 2.5 mM Ca (HBS-Ca). The diluted
phospholipid suspension (10 L) was incubated with 50 nM FITC–annexin
V (a concentration resulting in saturation of the PS present in the assay, as
determined experimentally) in HBS-Ca in coated microcentrifuge tubes
(Slickseal; National Scientiﬁc, Claremont, CA). After incubation at 37°C
for 15 minutes, the mixtures were centrifuged at 16 000g for 20 minutes.
The pellets were washed in HBS-Ca and then resuspended in HBS-Ca
containing various amounts of each of the unlabeled competing proteins
(annexin V, sTF-annV, or sTFAA-annV). After an additional 12 hours of
incubation at 37°C, the mixtures were centrifuged and the pellets washed in
HBS-Ca. The pellets were then resuspended in HBS plus 10 mM EDTA
and incubated for 16 hours at room temperature to elute bound FITC–
annexin V. The tubes were centrifuged and the supernatant ﬂuid was
removed. The amount of FITC-annexin in the supernatant was determined
by measuring its ﬂuorescence (excitation wavelength, 485 nm; emission
wavelength, 535 nm) in a ﬂuorescent microplate reader (Victor2, Wallac;
PerkinElmer, Boston, MA).
Factor VII autoactivation assay
The ability of the chimeric proteins to promote the autoactivation of factor
VII was assessed by adding each (ﬁnal concentration, 80 nM) to factor VII
(ﬁnal concentration, 80 nM) in 0.1 M NaCl, 50 mM Tris-HCl, 0.1% bovine
serum albumin, pH 7.4 (TBS) with 5 mM CaCl2 (TBS/Ca). For
experiments using sTF-annV or sTF, PC/PS vesicles were added to the
incubation mixtures at a composition and concentration identical to that
present in the native TF preparation (total phospholipid concentration,
810 M; PC/PS molar ratio  4:1). At selected intervals, 10-L aliquots
were removed from each incubation mixture and transferred to polystyrene
tubes containing 40 L TBS plus 5 mM EDTA to stop the reaction. The
amount of factor VIIa generated was assayed by adding 150 LTBS/Ca,
excess sTF, and Chromozym t-PA(ﬁnal concentrations, 5 mM, 124 nM, and
5 mM, respectively) and measuring the change inA405.
Factor VIIa binding assay
The sTF/TF-induced increase in factor VIIa amidolytic activity was used to
quantify the binding of these proteins to factor VIIa. Increasing concentra-
tions of sTF-annV, sTFAA-annV, or sTF were incubated with factor VIIa
(5 nM) in TBS/Ca in 96-well assay plates. After 10 minutes at room
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of substrate hydrolysis was measured at 405 nm using a microplate reader
(Molecular Devices, Menlo Park, CA). The background activity of factor
VIIa in the absence of sTF, sTF-annV, or sTFAA-annV was subtracted from
the measured values. Kinetic parameters were calculated using Prism 4
(GraphPad Software, San Diego, CA).
Factor X activation
The activation of factor X by factor VIIa in the presence of sTF, sTF-annV,
sTFAA-annV, or native relipidated TF was monitored in a continuous
one-stage assay. sTF, sTF-annV, sTFAA-annV, or native TF was added to
1 nM factor VIIa, factor X, PC/PS (molar ratio, 4:1), and 0.5 mM
Chromozym X in TBS/Ca. The rate of chromogenic substrate hydrolysis
(change inA405) was monitored over 20 minutes and converted to factor Xa
concentrations by reference to a standard curve prepared with puriﬁed
human factor Xa. The derivative of the resulting parabolic progress curve
was taken (Softmax Pro; Molecular Devices) to determine the rate of factor
Xa generation, and kinetic parameters were calculated using Prism 4
(GraphPad Software).
Plasma coagulation assays
Coagulation times. Clotting times of normal human citrated plasma
following the addition of CaCl2 in the presence of various concentrations of
recombinant proteins and PC/PS (molar ratio, 4:1) were measured with a
mechanical coagulometer (ST-4; Diagnostica Stago, Parsippany, NJ), which
had an upper limit of measurement of 999 seconds.
Dilute activated partial thromboplastin time. A commercially avail-
able aPTTreagent (DadeActin; Dade Behring) was diluted 1:50 inTBS and
used to measure the coagulation time of citrated human plasma in the
presence of various concentrations of sTF, annexin V, or sTF-annV. Plasma
was incubated with dilute aPTT reagent and recombinant proteins for 3
minutes at 37°C, followed by the addition of 25 mM CaCl2. The time
required for a clot to form was measured with a mechanical coagulometer.
Activated partial thromboplastin time (aPTT). The aPTT of plasma
containing either 1 unit/mL heparin sodium (American Pharmaceutical
Partners, Los Angeles, CA) or enoxaparin sodium (Aventis Pharmaceuti-
cals, Bridgewater, NJ) and various concentrations of sTF-annV or factor
VIIa was measured with a commercially available aPTT reagent (Actin
FSL; Dade Behring) according to the manufacturer’s instructions.
Mouse tail-bleeding times
Mice were housed in accordance with and studied using a protocol
approved by the University of Oklahoma Health Sciences Center Institu-
tionalAnimal Care and Use Committee.They were injected subcutaneously
with enoxaparin sodium and 2 hours later were anesthetized with pentobar-
bital (60 mg/kg, given intraperitoneally). The tail was warmed in normal
saline at 37°C, transected with a scalpel blade at a point where it was 2 mm
in diameter, and then placed in a tube of normal saline maintained at 37°C.
The time required for bleeding to stop was recorded. In preliminary
dose-ﬁnding experiments, increasing doses of enoxaparin sodium were
administered. Once a suitable dose was identiﬁed (20 mg/kg), a second
bleeding time was performed 5 minutes after the ﬁrst. The additional
bleeding time was performed by transecting the tail at a point 5 mm
proximal to the ﬁrst. The second bleeding times were not signiﬁcantly
different from the ﬁrst (P  .3, 2-tailed, paired t test, Prism 4; Graphpad
Software). Untested animals were then treated in a similar manner, but
received an intravenous injection of sTF-annV (90 g/kg) immediately
after the ﬁrst bleeding time determination. A second bleeding time was
performed 5 minutes after the injection.A2-tailed, paired t test was used to
compare the 2 bleeding times. An additional group of animals were then
studied. Two hours after the subcutaneous injection of saline or enoxaparin
(20 mg/kg), mice were given intravenous injections of sTF-annV (90 g/
kg), saline, sTF, annexin V, or a combination of sTF and annexin V. All
proteins were injected in amounts equimolar with sTF-annV. Tail-bleeding
times were measured 10 minutes later.
Results
Expression and puriﬁcation of annexin V and annexin
V chimeras
cDNA constructs encoding 3 proteins (annexin V, sTF-annV, and
sTFAA-annV) were expressed in the periplasmic space of E coli
and the proteins were puriﬁed by immobilized metal afﬁnity
chromatography (see Figure 1 for analyses of the puriﬁed proteins
by SDS-PAGE and Western blotting).
sTF-annV accelerates plasma coagulation
In initial studies, the abilities of sTF, native TF, and sTF-annV to
accelerate plasma coagulation in the presence of identical concen-
trations of added phospholipid and CaCl2 were compared. As
shown in Figure 2A, sTF-annV and native TF shortened the plasma
coagulation time to a much greater extent than did sTF. A dilute
aPTT assay was then used to determine whether the effects of
sTF-annV could be duplicated by adding sTF to annexin V. Plasma
was recalciﬁed in the presence of dilute aPTT reagent (used as a
source of phospholipid) and sTF, annexin V, the combination of
sTF and annexin V, or sTF-annV. As shown in Figure 2B, the
simultaneous addition of sTF and annexin V did not reproduce the
procoagulant effect of sTF-annV. Under these conditions, sTF-
annV demonstrated a biphasic effect on plasma coagulation,
prolonging coagulation at higher concentrations.
These results suggested that at lower concentrations the proco-
agulant effect was due to the sTF domain, while at higher
concentrations the anticoagulant effect of annexin V predominated.
To test this hypothesis, a construct was prepared in which the
lysines at positions 165 and 166 of the TF/sTF domain were
mutated to alanine, a change known to impair factor X activa-
tion.24,27 The resulting chimera (sTFAA-annV) also exhibited
biphasic effects on plasma coagulation (Figure 2C), but had less
procoagulant activity than sTF-annV and exhibited its anticoagu-
lant activity at lower concentrations. Given the evidence that
sTF-annV and sTFAA-annV were able to alter plasma coagulation,
Figure 1. Protein puriﬁcation and Western blotting of recombinant proteins.
Top: SDS-PAGE and Coomassie blue staining. Middle: Western blot using a mouse
monoclonal antibody to human TF. Bottom: Western blot using mouse monoclonal
antibody to His6. M indicates molecular weight marker. Lanes 1 to 5 are identical in
panelsA, B, and C: lane 1, sTF–annexin V; lane 2, sTFAA–annexin V; lane 3, annexin
V; lane 4, sTF; and lane 5, recombinant TF.18 Lane 6, panelA: bovine serum albumin;
panels B and C: recombinant TF (Innovin; Dade Behring).
982 HUANG et al BLOOD, 1 FEBRUARY 2006 VOLUME 107, NUMBER 3
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From detailed functional characterization of their constituent domains
was undertaken.
Phospholipid binding activity
The ability of sTF-annV and sTFAA-annV to bind PS was assessed
with a modiﬁcation of a published PS-binding assay26 in which
annexin V, sTF-annV, or sTFAA-annV competed with FITC–
annexinVfor binding to phospholipid vesicles.As shown in Figure
3, both chimeras exhibited PS-binding activity comparable with
annexin V. The Kd for annexin V was 12 nM; for sTF-annV, 13 nM;
and for sTFAA-annV, 11 nM.
Factor VII autoactivation activity
It has been shown previously that TF, but not sTF, promotes
autoactivation of factor VII in the presence of PS and Ca.3,28 The
failure of sTF to accelerate factor VII autoactivation has been
attributed to the low afﬁnity of sTF:VIIa complexes for PS-
containing membranes.29 Since the annexin V domain of the
chimera exhibited high afﬁnity for PS-containing liposomes, we
postulated that sTF-annV would promote factor VII autoactivation
in a manner comparable to TF, rather than sTF.As shown in Figure
4, sTF-annV promoted factor VII autoactivation at a rate compa-
rable to native TF, rather than sTF (which was inactive). These
results also suggest that sTF-annV is able to bind factor VII as well
as native TF.
Factor VIIa binding activity
To measure the binding of factor VIIa to the chimeras, we
quantiﬁed the increase in factor VIIa’s amidolytic activity when it
binds to TF/sTF.30 Because sTF does not bind membranes well, we
performed the analysis in the absence of PS. Both sTF-annV and
sTFAA-annV increased the amidolytic activity of factor VIIa to the
same extent as sTF, indicating that the annexin V domain did not
interfere with the ability of the sTF domain to bind factorVIIa (data
not shown). The Kd for binding of factor VIIa to sTF was 8.17 nM;
for sTF-annV, 7.05 nM; and for sTFAA-annV, 3.47 nM, all in the
absence of phospholipid vesicles.
Factor X activation
The effect of sTF-annV and sTFAA-annV on the rate of factor X
activation by factor VIIa was assessed.As shown in Figure 5A, the
rate of factor X activation in the presence of either sTF-annV or
sTFAA-annV was greater than that seen in the presence of sTF. As
expected from prior studies of sTFAA,24,27 sTF-annV was more
potent than sTFAA-annV in supporting factor X activation. As
shown in Table 1, the catalytic efﬁciency (kcat/Km) of factor VIIa in
the presence of sTF-annV was approximately 67% of that found in
the presence of native TF, but approximately 5-fold greater than
that of sTFAA-annV.
Since high concentrations of sTF-annV were associated with
prolongation of the plasma coagulation times, we studied the effect
of increasing concentrations of sTF-annV on the rate of factor X
activation by factor VIIa. As shown in Figure 5B, sTF-annV
exhibited a biphasic effect on factor X activation, paralleling its
effects on plasma coagulation.
Figure 2. Inﬂuence of recombinant proteins on plasma coagulation. (A) The coagulation time of citrated human plasma with different concentrations of native TF (f), sTF
( ), or sTF-annV (F).The total amount of PC/PS added to each sample was 10 M (PC/PS molar ratio, 4:1). Shown are means  SEM. (B) Plasma coagulation times with sTF
( ), annexin V (Œ), both sTF and annexin V (), or sTF-annV (F) measured using a dilute partial thromboplastin time protocol, as described in “Materials and methods.” (C)
Plasma coagulation times, in the absence of added phospholipids, with different concentrations of sTF ( ), annexin V (Œ), sTF-annV (F), or sTFAA-annV (E). Shown are
means  SEM.
Figure 3. Phospholipid binding of sTF-annV and sTFAA-annV. The ability of
sTF-annV( )andsTFAA-annV(Œ)tobindPC/PSvesicleswascomparedwiththatof
annexin V (■) by assessing the ability of each protein to displace FITC–annexin V
from a phospholipid suspension, as described in “Materials and methods.” The
curves were computer-generated using nonlinear regression and a one-site ligand-
binding equation. Data are expressed as the percent (mean  SEM) of EDTA-
elutable ﬂuorescence.
Figure 4.Autoactivation of factor VIIa in the presence of native TF, sTF-annV, or
sTF. Factor VII (80 nM) was added to equimolar concentrations of native TF (f), sTF
( ), or sTF-annV (F) in the presence of PC/PS (810 M, PC/PS molar ratio  4:1)
and CaCl2. At the indicated times, aliquots were removed and the reaction was
stopped by dilution in EDTA-containing solutions. The factor VIIa content of each
sample was then determined by measuring the rate of hydrolysis of Chromozym t-PA
in the presence of added sTF and CaCl2. Shown are means  SEM.
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Heparin is a commonly used anticoagulant that works by enhanc-
ing the ability of the serpin, antithrombin, to inhibit (primarily)
factor Xa and thrombin.31 We added unfractionated heparin sodium
or enoxaparin, a low-molecular-weight heparin, to citrated plasma
along with various concentrations of sTF-annV and then deter-
mined the plasma aPTT. sTF-annV shortened the aPTT of plasma
containing either 1 unit/mL unfractionated heparin (Figure 6A) or
1 U/mL enoxaparin (Figure 6B). Factor VIIa, used as a therapeutic
agent to treat bleeding in numerous clinical conditions associated
with decreased thrombin generation,32 also decreased the aPTT of
heparin-treated plasma, although less potently than sTF-annV
(Figure 6A-B).
Effect of sTF-annV on mouse tail-bleeding times
Although the template bleeding time assay in humans is thought to
predominantly reﬂect platelet function, defects in thrombin genera-
tion in mice are reﬂected by prolonged bleeding times.33-36 We
therefore administered enoxaparin to normal mice to determine
whether sTF-annV would affect an in vivo measure of thrombin
generation. Mice were injected subcutaneously with enoxaparin
sodium (20 mg/kg), a drug known to inhibit thrombin generation,31
and the bleeding time was measured 2 hours later. After the
bleeding from the bleeding time wound stopped, the animals were
given an intravenous injection of sTF-annV (90 g/kg) and the
bleeding time was repeated 5 minutes later. (Preliminary experi-
ments showed that a second bleeding time in enoxaparin-treated
animals was not signiﬁcantly different from the ﬁrst, P  .3, paired
2-tailed t test.) As shown in Figure 7A, sTF-annV signiﬁcantly
shortened the bleeding time of enoxaparin-treated mice (P  .01,
paired 2-tailed t test). Enoxaparin treatment resulted in a mean
bleeding time of 10.7 minutes (median, 6.1 minutes). The mean
bleeding time after sTF-annV treatment was 1.4 minutes (mean,
1.1 minutes). The mean bleeding time of untreated animals was
1.2 minutes.
The tail-bleeding time was measured in additional groups of
mice. sTF-annV shortened the bleeding time of animals not treated
with enoxaparin (1.5  0.7 minute versus 3.6  0.2 minute,
P  .02, unpaired t test with Welch correction; Figure 7B). Naive
animals were then treated with enoxaparin (20 mg/kg, subcutane-
ously) 2 hours before they were injected intravenously with
sTF-annV (90 g/kg) or equimolar amounts of sTF, annexin V, or
the combination of sTF and annexin V. As shown in Figure 7B,
shortening of the bleeding time was seen only in animals treated
with sTF-annV (P  .001, 2-tailed unpaired t test with Welch
correction), showing that the chimera itself, and not its indi-
vidual constituents, was responsible for the shortening of the
bleeding time.
Discussion
Previous studies have shown that the isolated extracellular domain
of TF (sTF) retains a conformation sufﬁcient to allow binding to
Figure 6. The effect of sTF-annV or factor VIIa on the aPTT of heparin-treated
plasma. (A) aPTT assays of plasma containing heparin sodium (1 unit/mL) were
measured in the presence of various concentrations of factor VIIa (F) or sTF-annV
(f). (B) The aPTT of plasma containing enoxaparin sodium (1 unit/mL) was
measured in the presence of various concentrations of factor VIIa (F) or sTF-annV
(f). The dotted lines show the mean clotting time for the aPTT assay in the absence
of heparin or enoxaparin. Shown are means  SEM. (Most error bars are too small to
be seen.)
Figure 7. The effect of sTF-annV on the tail-bleeding time. (A) Mice (n  13) were
given a subcutaneous injection of enoxaparin sodium (20 mg/kg), and 2 hours later
they were anesthetized and the tail-bleeding time was determined as described in
“Materials and methods.” Immediately upon the cessation of bleeding, the animals
were injected intravenously with sTF-annV (90 g/kg) in TBS. Five minutes later, the
bleeding time was measured again. The differences were signiﬁcant at a level of
P  .01(paired2-tailedttest).(B)Tail-bleedingtimesweremeasuredasdescribedinpanel
A. Two hours after receiving subcutaneous enoxaparin (or saline), animals were injected
intravenously with sTF-annV (90 g/kg) or equivalent molar amounts of sTF, annexin V, or
both sTF and annexin V. Tail-bleeding times were measured 10 minutes later. sTF-annV
shortened the bleeding time of mice that did not receive enoxaparin (P  .2) as well as
those that did (P  .001, 2-tailed unpaired t test with Welch correction). Two animals were
studied in each of the groups that did not receive enoxaparin, and 4 in each of the
enoxaparin-treated groups. Shown are the means SEM.
Figure 5. Generation of factor Xa by factor VIIa in the presence of recombinant
proteins. (A) Various concentrations of factor X were added to 1 nM factor VIIa, 5 M
PC/PS (molar ratio, 4:1), 5 mM CaCl2, and Chromozym X substrate in the presence of
5 pM native TF (f), sTF ( ), sTF-annV (F), or sTFAA-annV (E). Initial rates of
substrate hydrolysis were measured as described in “Materials and methods,” to
which the Michaelis-Menten equation was ﬁtted. (B) Initial rates of factor Xa
generation were measured in solutions containing 28 nM factor X, 5 mM CaCl2,1n M
factor VIIa, 0.347 M PC/PS, and various concentrations of sTF ( ) or sTF-annV (F).
Shown are the means  SEM. (Most error bars are too small to be seen.)
Table 1. Effect of sTF, sTF-annexin V, and sTFAA-annV on the rate of
factor X activation by factor VIIa
Cofactor Vmax, nM  min1 Km,n M kcat,s 1 kcat/Km, M1s1
TF 0.71  0.008 46  1 2.37 51.5
sTF-annV 0.66  0.03 64  7 2.2 34.4
sTFAA-annV 0.71  0.06 389  58 2.37 6.1
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synthetic substrate.3,37 sTF is much less efﬁcient in promoting the
activation of factor X by factor VIIa, however. This appears to be
due to relatively low afﬁnity of sTF and the sTF-VIIa complex for
membrane surfaces.29 By substituting a glycosylphosphatidylinosi-
tol anchor for the TF transmembrane domain, Paborsky et al were
able to create a membrane-bound sTF variant that had full
procoagulant activity, indicating the ability of sTF to function as
well as native TF if appropriately tethered to a cell surface.4
Others have coupled sTF to peptide moieties and demonstrated
activation of the coagulation system in vitro and in vivo.38-42 Each
used a targeting domain speciﬁc for a particular cell type or
anatomic region, and all of these studies were directed toward
developing anticancer agents, rather than novel hemostatic compounds.
In this study, a chimeric protein that contained the sTF domain
was created with several novel features: (1) it was designed to be
“polyspeciﬁc” with regard to the cell types that play a role in
hemostasis; (2) it used a membrane-targeting domain that has
anticoagulant properties, and therefore raised questions about the
likelihood that the chimera would be procoagulant; and (3) it was
anticipated that its effectiveness as a procoagulant would depend
upon the local concentration of anionic extracellular phospholipids.
Thus, although annexin V’s potency as a PS-binding protein made
it attractive as a targeting moiety, its anticoagulant action cautioned
against its use in a construct designed to be a procoagulant
hemostatic agent.
The initial studies of sTF-annV were therefore directed toward
determining whether it was in fact procoagulant, and if so, how its
procoagulant activity compared with that of both sTF and native
TF. Because we recognized that the ratio of annexin V to
phospholipid would be important, we used phospholipid suspen-
sions, rather than activated cells, to maintain consistency, during
our analysis. Once we found that sTF-annV was procoagulant
(Figure 2A), we established that the procoagulant activity was
speciﬁc to the chimera, and could not be reproduced by adding
equimolar amounts of a mixture of sTF and annexin V (Figure 2B).
We also prepared a chimera in which amino acids 165 and 166 of
sTF were mutated from lysine to alanine, a change known to
signiﬁcantly reduce the procoagulant activity of TF,24,27 and found
that it had diminished procoagulant activity (Figure 2C). Finally,
we explored the consequences of altering the ratio of the chimera to
the PS present in the reaction mixture. We found that for both
sTF-annV and sTFAA-annV, an increase in the protein/PS ratio
beyond a certain point resulted in an anticoagulant effect (Figure
2C). Thus, targeting of sTF to a membrane surface by the annexin
V domain is procoagulant when there is a functional excess of
PS-bearing sites that can bind other coagulation factors. As the
amount of annexin V present increases, those sites become less
accessible to coagulation factors VII/VIIa, X, VIII, IX, V, and II,
and coagulation slows.
We then conducted analyses of the functional domains compris-
ing sTF-annVto determine if linking them together caused a loss or
gain of function of either. Tests of the chimera’s ability to bind
PS-containing vesicles (Figure 3), promote factor VII autoactiva-
tion (Figure 4), and enhance factor VIIa’s amidolytic and factor
X–cleaving activity (Figure 5) indicated that both the sTF and
annexin V domains were functional, although native TF promoted
the catalytic efﬁciency of factor VIIa toward factor X twice as well
as did sTF-annV (Table 1).
These studies indicated that sTF-annV could function as a
procoagulant, but its procoagulant activity was heavily dependent
upon the phospholipid concentration. Since the local concentration
of PS at a wound site in vivo is not precisely known, in vitro
experiments have limited ability to predict the behavior of a PS
binding protein (such as sTF-annV) in vivo. In order to test
sTF-annV in vivo under conditions where the PS concentration
would be determined by the body’s response to injury, we
performed tail-bleeding times in mice, a method known to be
sensitive to defective thrombin generation36,43,44 in the setting of
the prior administration of enoxaparin, a low-molecular-weight
heparin used to impair thrombin generation.31 In preparation for this
experiment,westudiedtheeffectofsTF-annVonplasmacoagulationin
the presence of enoxaparin, as well as unfractionated heparin, and
contrasted it with the effects of factor VIIa, a protein currently used to
treat patients with a variety of bleeding disorders.32 Both factorVIIa and
sTF-annV shortened the coagulation time of heparin- and enoxaparin-
treated plasma, although sTF-annV was several orders of magnitude
more potent than factorVIIa (Figure 6).
We treated mice with increasing doses of enoxaparin, establish-
ing a dose that increased 2 sequential bleeding times reproducibly.
We then injected sTF-annV by intravenous tail-vein injection
between the ﬁrst and second tail-bleeding time. In all animals
tested, the second bleeding time was signiﬁcantly shorter than the
ﬁrst. Using additional animals, we found that the effect of
sTF-annVcouldnotbereproducedbyinjectingsTF,annexinV,ora
mixture of the two. Because human factorVIIa is not fully active in
mouse plasma,45 it could not be used for direct comparisons. The
dose of sTF-annV was chosen because it is equivalent (on a weight
basis) to a commonly recommended recombinant factor VIIa dose.
Further studies will be required to determine the optimal dose of
sTF-annV to be used, which may well vary in different clinical
situations, depending upon the local PS concentration and the
magnitude of the vascular injury.
These studies demonstrate that seemingly antagonistic protein
domains may be combined in a chimeric molecule to generate a
protein whose activity is not simply determined by the net effect of
its dominant domain. sTF-annV exhibits an effect that is reﬂective
of either of its opposing domains, depending upon the conditions.
TheabilityofsTF-annVtoexhibitbothprocoagulantandanticoagu-
lant activity makes it unique among hemostatic molecules. Further
work in vivo may demonstrate that sTF-annV can be used as a
probe of the local PS concentration, as reﬂected, for example, by its
effect on thrombin generation in shed blood. Such a determination
may be of therapeutic, as well as experimental, importance. For
example, if the local PS concentration is very low (as may be the
case at sites of bleeding in thrombocytopenic individuals), a
procoagulant dose of sTF-annV might be unduly anticoagulant,
thereby worsening an individual’s bleeding. Alternatively, if some
stimuli, such as massive trauma, result in high local concentrations
of PS, higher doses of sTF-annV might be safely used to rapidly
obtain hemostasis and prevent the subsequent deleterious effects of
major blood loss. If the hypothesis that local concentrations of PS
differ (depending upon the clinical circumstances) is correct,
studies of the microenvironment unique to different types and sites
of vascular injury may stimulate the development of new hemo-
static compounds.
Others have shown that targeting sTF to tumors with coaguloli-
gands,39 chimeric proteins that target sTF to speciﬁc vascular beds by
tethering it to tumor-speciﬁc antibodies or ligands, can lead to obstruc-
tion of the tumor vasculature and cell death.38-42,46 Since PS is not
present on normal blood vessels, but is found on cells within tumor
blood vessels,47,48 as well as on the surface of apoptotic tumor49-51 and
endothelial52 cells, sTF-annV may also ﬁnd use as an anticancer agent
when given alone or in conjugation with other therapies.
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